Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

Eli Lilly's stock has been a strong winner over ... For its part, Lilly has teamed with Hims & Hers' competitor Ro to offer cheaper prices for Zepbound and to better compete with the compounders.

FDA has ordered specialty pharmacies and online companies to phase out knockoff versions of Eli Lilly blockbuster drugs ...

Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...

Lilly is investing billions of dollars to scale manufacturing efforts as demand for its weight loss treatments soar. The ...

Eli Lilly (LLY) has announced it will make lower-priced, single-dose vials of its popular weight-loss treatment Zepound available on telehealth platform Ro. Starting today, consumers can get an ...

Eli Lilly, which has been directing patients to ... announcing a partnership Wednesday with major telehealth platform Ro. Under the new agreement, Ro patients who are prescribed Zepbound will ...